Terms: = Ovarian cancer AND TRA AND Treatment
8 results:
1. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract] [Full Text] [Related]
2. HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis.
Wang Z; Guo B; Yue S; Zhao S; Meng F; Zhong Z
Int J Pharm; 2022 Sep; 625():122126. PubMed ID: 35995316
[TBL] [Abstract] [Full Text] [Related]
3. HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted treatment of ovarian Tumor.
Ding L; Gu W; Zhang Y; Yue S; Sun H; Cornelissen JJLM; Zhong Z
Biomacromolecules; 2019 Oct; 20(10):3855-3863. PubMed ID: 31513391
[TBL] [Abstract] [Full Text] [Related]
4. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.
Sato K; Hanaoka H; Watanabe R; Nakajima T; Choyke PL; Kobayashi H
Mol Cancer Ther; 2015 Jan; 14(1):141-50. PubMed ID: 25416790
[TBL] [Abstract] [Full Text] [Related]
5. Effect of tra-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
Frederick PJ; Kendrick JE; Straughn JM; Della Manna DL; Oliver PG; Lin HY; Grizzle WE; Stockard CR; Alvarez RD; Zhou T; LoBuglio AF; Buchsbaum DJ
Int J Gynecol Cancer; 2009 Jul; 19(5):814-9. PubMed ID: 19574765
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy of anti-death receptor 5 (DR5) antibody (tra-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
Estes JM; Oliver PG; Straughn JM; Zhou T; Wang W; Grizzle WE; Alvarez RD; Stockard CR; LoBuglio AF; Buchsbaum DJ
Gynecol Oncol; 2007 May; 105(2):291-8. PubMed ID: 17303227
[TBL] [Abstract] [Full Text] [Related]
7. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract] [Full Text] [Related]
8. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) ovarian cancer Study Group.
Hilpert F; Stähle A; Tomé O; Burges A; Rossner D; Späthe K; Heilmann V; Richter B; du Bois A;
Support Care Cancer; 2005 Oct; 13(10):797-805. PubMed ID: 16025262
[TBL] [Abstract] [Full Text] [Related]
